Successful oral desensitization with dasatinib in delayed cutaneous hypersensitivity reactions

2019 ◽  
Vol 123 (2) ◽  
pp. 216-217 ◽  
Author(s):  
Betul Karaatmaca ◽  
Selin Aytac ◽  
Umit Murat Sahiner ◽  
Bulent Enis Sekerel ◽  
Ozge Soyer
Keyword(s):  
Hypersensitivity Reactions ◽  
Cutaneous Hypersensitivity ◽  
Delayed Cutaneous Hypersensitivity ◽  
Oral Desensitization

Delayed Cutaneous Hypersensitivity Reactions to Hirudin

2001 ◽  
Vol 125 (12) ◽  
pp. 1585-1587
Author(s):  
Kathleen J. Smith ◽  
Juan Rosario-Collazo ◽  
Henry Skelton
Keyword(s):  
Primary Treatment ◽  
Myocardial Infarctions ◽  
Hypersensitivity Reactions ◽  
Type Ii ◽  
Antithrombotic Agent ◽  
Heparin Induced Thrombocytopenia ◽  
Cutaneous Hypersensitivity ◽  
History Of ◽  
Delayed Hypersensitivity Reaction ◽  
Delayed Cutaneous Hypersensitivity

Abstract Hirudin is one of the new synthetic antithrombin agents, which is most commonly used in patients with type II heparin-induced thrombocytopenia and in patients with hypersensitivity reactions to unfractionated heparin as well as low-molecular-weight heparins. Hirudin is comparable to heparin as an antithrombotic agent and also has been studied as a primary treatment in patients who experienced acute myocardial infarctions. We describe a patient with a history of type II heparin-induced thrombocytopenia who was placed on intravenous hirudin therapy. After extravasation of the intravenous hirudin site, the patient developed a delayed hypersensitivity reaction that histologically showed an epithelioid granulomatous infiltrate. Although rare reports of hypersensitivity reactions to hirudin have been published, these reactions have not been well characterized and the histopathologic changes have not been described.

Delayed Cutaneous Hypersensitivity Reactions in Qigong (Chun Do Sun Bup) Trainees by Multitest Cell Mediated Immunity

1995 ◽  
Vol 23 (02) ◽  
pp. 139-144 ◽  
Author(s):  
Hoon Ryu ◽  
Haeng Yoeng Mo ◽  
Gui Dal Mo ◽  
Byung Min Choi ◽  
Chang Duk Jun ◽  
...  
Keyword(s):  
Healthy Subjects ◽  
Healthy Person ◽  
Skin Tests ◽  
Cell Mediated Immunity ◽  
Hypersensitivity Reactions ◽  
Healthy Group ◽  
Trainee Group ◽  
Cutaneous Hypersensitivity ◽  
The Difference ◽  
Delayed Cutaneous Hypersensitivity

To determine the difference of cellular immunity between a Qigong trainee group and a normal healthy group, skin tests for delayed cutaneous hypersensitivity (DCH) were carried out with ubiquitous seven antigens. The maximal antigen response time was faster in Qigong trainee group (24 hr) and the response antigen number was also higher in the Qigong trainee group (6 antigens) than in normal healthy person (48 hr and 4 antigens). Qigong trainee also had a larger induration diameter (5.14 mm) than normal healthy person (3.79 mm) at 24 hr. Our results represent the difference in cell mediated immunity (CMI) between Qigong trainees and normal healthy subjects.

Delayed Cutaneous Hypersensitivity Reaction to Carcinoembryonic Antigen in Cancer Patients

1982 ◽  
Vol 68 (6) ◽  
pp. 473-475 ◽  
Author(s):  
Sergio Orefice ◽  
Giuseppe Fossati ◽  
Enrico Pietrojusti ◽  
Giuliano Bonfanti
Keyword(s):  
Hypersensitivity Reaction ◽  
Carcinoembryonic Antigen ◽  
Skin Test ◽  
Positive Skin Test ◽  
Hypersensitivity Reactions ◽  
Degenerative Diseases ◽  
Positive Skin ◽  
Cutaneous Hypersensitivity ◽  
Test Reactions ◽  
Delayed Cutaneous Hypersensitivity

The delayed cutaneous hypersensitivity reaction to carcinoembryonic antigen (CEA) was tested in 84 patients with different diseases including large bowel adenocarcinoma and breast carcinoma, with or without metastasis, liver cirrhosis and inflammatory or degenerative diseases. Positive skin test to CEA was observed in a small proportion (11 %) of the patients tested. No difference in positive skin test reactions was observed in the 6 different groups of patients. Similar delayed cutaneous hypersensitivity reactions were found to various amount of CEA ranging from 0.5 to 25 μg. No correlation was seen between the results of skin test and blood CEA levels.

Immediate reaction to ibrutinib amenable to oral desensitization

2021 ◽  
pp. 107815522110046
Author(s):  
Neelam A Phadke ◽  
Samantha O Luk ◽  
Ephraim P Hochberg ◽  
Aleena Banerji
Keyword(s):  
Maculopapular Rash ◽  
Chemotherapeutic Agents ◽  
Lymphocytic Leukemia ◽  
Hypersensitivity Reactions ◽  
First Line ◽  
Management Guidelines ◽  
Cutaneous Hypersensitivity ◽  
Ige Mediated ◽  
To Receive ◽  
Oral Desensitization

Introduction Although up to half of patients receiving chemotherapeutic agents develop hypersensitivity reactions to the same, desensitization protocols can induce temporary tolerance to allow patients to continue to receive first-line treatment. Approximately 25% of patients develop cutaneous hypersensitivity reactions to ibrutinib, but there are no published management guidelines. Case report We describe the case of a 71-year-old woman with chronic lymphocytic leukemia who developed a delayed maculopapular rash with lip tingling and swelling following ibrutinib therapy. Management and outcome We performed a novel 11-step desensitization procedure to ibrutinib allowing us to successfully induce tolerance against IgE-mediated symptoms in this patient. Discussion As indications for ibrutinib use expand and more patients present with IgE-mediated symptoms, we expect that this protocol will provide benefit for many such patients.

Delayed cutaneous hypersensitivity reactions to iodinated contrast media

2017 ◽  
Vol 27 (2) ◽  
pp. 190-191
Author(s):  
Caroline Corbaux ◽  
Julien Seneschal ◽  
Alain Taïeb ◽  
François Cornelis ◽  
Jeremie Martinet ◽  
...  
Keyword(s):  
Contrast Media ◽  
Hypersensitivity Reactions ◽  
Iodinated Contrast Media ◽  
Iodinated Contrast ◽  
Cutaneous Hypersensitivity ◽  
Delayed Cutaneous Hypersensitivity
Sign in / Sign up

Export Citation Format

Share Document